Core Viewpoint - The article highlights the rapid growth and opportunities in the domestic electrophysiology market, driven by favorable policies and technological advancements, with a focus on the company's comprehensive solutions in cardiac electrophysiology [4][5]. Industry Overview - The domestic electrophysiology market is experiencing a high growth period, with significant increases in traditional radiofrequency and cryoablation technologies, as well as new pulse ablation technologies injecting vitality into the market [5]. - The market share of foreign brands like Johnson & Johnson is decreasing, with the industry's CR5 dropping from 93% in 2020 to 72% in 2024, indicating a shift towards domestic alternatives [5]. - Policies such as the "14th Five-Year" medical equipment industry development plan are key drivers for market growth, while DRG and volume-based procurement are opening up channels for domestic products [5]. Company Performance - The company, established in 2010, specializes in electrophysiological intervention and ablation treatment, achieving a revenue of 413 million yuan in 2024, a year-on-year increase of 25.51%, and a net profit of 52 million yuan, up 815.36% year-on-year [4]. - The company has a complete product line covering two-dimensional and three-dimensional series, with a leading matrix of measurement, ablation, equipment, and accessories [7]. - The company's ablation catheter products are deeply compatible with the core Columbus three-dimensional mapping system, creating synergistic advantages [7]. Technological Advancements - The company is driving breakthroughs in multiple fields through independent research and development, creating several domestically innovative products that cover key areas such as radiofrequency, cryoablation, pulse ablation, and three-dimensional mapping [7]. - The company has achieved over 1100 hospital coverage for three-dimensional surgeries, with a cumulative total of over 70,000 cases by 2024 [7]. - The company is also making strides in emerging fields, with the PulseMagic catheter for pulse ablation expected to be approved in November 2025, and a self-developed catheter for renal artery treatment [7].